/PRNewswire/ Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient was dosed in NCT05468489, a bridging head-to-head trial in the United.
Palleon and Henlius to co-develop Bifunctional HER2-Sialidase and a second bifunctional sialidase to be jointly designed - Henlius received exclusive license for two products in China (including Hong Kong, Macau, and Taiwan); Palleon retains all other global rights - Palleon receives upfront payment and is eligible for up to $196.5 million in milestone payments - SHANGHAI, June 28, 2022 /PRNewswire/ Palleon Pharmaceuticals Inc., a companypioneering the field of glyco-immunology to treat cancer and inflammatory diseases, todayannounced a strategic collaboration with Shanghai Henlius Biotech, Inc. (2696.HK) to develop andcommercialize two bifunctional sialidase programs from Palleon's EAGLE (Enzyme-AntibodyGlyco-Ligand Editing) immuno-oncology platform, including Palleon's Bifunctional HER2-Sialidasenow in preclinical development and a second bifunctional sialidase to be developed with aproprietary target provided by Henlius. Palleon's EAGLE platform potentiates antitumor im